Cargando…

Assessment tools for patient-reported outcomes in multiple myeloma

BACKGROUND: Patients with multiple myeloma experience severe symptom burden. Patient participation in self-reporting is essential as medical staff’s assessment of patient symptom severity is often lower than patient self-reporting. This article reviews patient-reported outcome (PRO) assessment tools...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ting, Lu, Qin, Tang, LeiWen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313577/
https://www.ncbi.nlm.nih.gov/pubmed/37389673
http://dx.doi.org/10.1007/s00520-023-07902-4
_version_ 1785067156153565184
author Wang, Ting
Lu, Qin
Tang, LeiWen
author_facet Wang, Ting
Lu, Qin
Tang, LeiWen
author_sort Wang, Ting
collection PubMed
description BACKGROUND: Patients with multiple myeloma experience severe symptom burden. Patient participation in self-reporting is essential as medical staff’s assessment of patient symptom severity is often lower than patient self-reporting. This article reviews patient-reported outcome (PRO) assessment tools and their application in the field of multiple myeloma. RESULTS: The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) is the universal patient-reported outcome assessment tool most frequently used to evaluate the life quality in people with multiple myeloma. Among the specific patient-reported outcome assessment tools, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Multiple Myeloma Module (EORTC QLQ-MY20), the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM), and the M.D. Anderson Symptom Inventory-Multiple Myeloma Module (MDASI-MM) are the most widely used, with some scholars using the EORTC QLQ-MY20 as a calibration correlate for scale development. Most current assessment instruments were developed using classical measurement theory methods; future researchers could combine classic theory tests and item response theory to create scientific assessment instruments. In addition, researchers select the appropriate assessment tool based on the purpose of the study. They can translate high-quality assessment tools into different languages and consider applying them more often to assessing multiple myeloma patients. Finally, most existing PROs focus on measuring life quality and symptoms in people with multiple myeloma, with less research on outcomes such as adherence and satisfaction, thus failing to comprehensively evaluate the patient treatment and disease management. CONCLUSIONS: Research has shown that the field of PROs in multiple myeloma is in an exploratory phase. There is still a need to enrich the content of PROs and develop more high-quality PRO scales for multiple myeloma based on the strengths and weaknesses of existing tools. With the successful advancement of information technology, PROs for people with multiple myeloma could be integrated with electronic information systems, allowing patients to report their health status in real time and doctors to track their condition and adjust their treatment, thereby improving patient outcomes.
format Online
Article
Text
id pubmed-10313577
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-103135772023-07-02 Assessment tools for patient-reported outcomes in multiple myeloma Wang, Ting Lu, Qin Tang, LeiWen Support Care Cancer Review BACKGROUND: Patients with multiple myeloma experience severe symptom burden. Patient participation in self-reporting is essential as medical staff’s assessment of patient symptom severity is often lower than patient self-reporting. This article reviews patient-reported outcome (PRO) assessment tools and their application in the field of multiple myeloma. RESULTS: The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) is the universal patient-reported outcome assessment tool most frequently used to evaluate the life quality in people with multiple myeloma. Among the specific patient-reported outcome assessment tools, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Multiple Myeloma Module (EORTC QLQ-MY20), the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM), and the M.D. Anderson Symptom Inventory-Multiple Myeloma Module (MDASI-MM) are the most widely used, with some scholars using the EORTC QLQ-MY20 as a calibration correlate for scale development. Most current assessment instruments were developed using classical measurement theory methods; future researchers could combine classic theory tests and item response theory to create scientific assessment instruments. In addition, researchers select the appropriate assessment tool based on the purpose of the study. They can translate high-quality assessment tools into different languages and consider applying them more often to assessing multiple myeloma patients. Finally, most existing PROs focus on measuring life quality and symptoms in people with multiple myeloma, with less research on outcomes such as adherence and satisfaction, thus failing to comprehensively evaluate the patient treatment and disease management. CONCLUSIONS: Research has shown that the field of PROs in multiple myeloma is in an exploratory phase. There is still a need to enrich the content of PROs and develop more high-quality PRO scales for multiple myeloma based on the strengths and weaknesses of existing tools. With the successful advancement of information technology, PROs for people with multiple myeloma could be integrated with electronic information systems, allowing patients to report their health status in real time and doctors to track their condition and adjust their treatment, thereby improving patient outcomes. Springer Berlin Heidelberg 2023-06-30 2023 /pmc/articles/PMC10313577/ /pubmed/37389673 http://dx.doi.org/10.1007/s00520-023-07902-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Wang, Ting
Lu, Qin
Tang, LeiWen
Assessment tools for patient-reported outcomes in multiple myeloma
title Assessment tools for patient-reported outcomes in multiple myeloma
title_full Assessment tools for patient-reported outcomes in multiple myeloma
title_fullStr Assessment tools for patient-reported outcomes in multiple myeloma
title_full_unstemmed Assessment tools for patient-reported outcomes in multiple myeloma
title_short Assessment tools for patient-reported outcomes in multiple myeloma
title_sort assessment tools for patient-reported outcomes in multiple myeloma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313577/
https://www.ncbi.nlm.nih.gov/pubmed/37389673
http://dx.doi.org/10.1007/s00520-023-07902-4
work_keys_str_mv AT wangting assessmenttoolsforpatientreportedoutcomesinmultiplemyeloma
AT luqin assessmenttoolsforpatientreportedoutcomesinmultiplemyeloma
AT tangleiwen assessmenttoolsforpatientreportedoutcomesinmultiplemyeloma